Distinct biological subtypes of chronic GVHD after pediatric hematopoietic cell transplantation

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Chronic graft-versus-host-disease (cGvHD) is a major complication after hematopoietic cell transplantation (HCT), often treated as a uniform condition.
• Understanding cGvHD's heterogeneity is crucial for improving patient outcomes and developing targeted therapies.

Purpose of the Study:

• To investigate the existence of distinct biological subtypes within cGvHD.
• To characterize these subtypes based on cellular, molecular, and clinical features.

Main Methods:

• Clustering analysis was performed on data from the largest pediatric cGvHD cohort (ABLE network).
• Subtypes were characterized by immune cell populations (e.g., TEM, NK cells, B cells, T cells) and molecular profiles.
• Metabolomic data from a separate cohort (COG trial ASCT0031) were used for partial replication.
• Clinical associations, including treatment exposures and onset, were analyzed.

Main Results:

• Three distinct cGvHD subtypes were identified: cGvHD-1 (effector memory T cells, cytotoxic NK cells, early B cells), cGvHD-2 (phosphatidylcholine, cytokines, plasma cells), and cGvHD-3 (naïve CD4+ T cells, naïve Tregs, TREC).
• Subtypes showed differential associations with treatments like serotherapy (ATG), stem cell source (PBSC), TBI, and prior acute GvHD.
• cGvHD-2 and -3 were associated with de novo cGvHD; cGvHD-2 with liver involvement.
• All identified subtypes shared common markers utilized in a previously developed cGvHD diagnostic classifier.

Conclusions:

• The study provides evidence for distinct biological subtypes of cGvHD, challenging the view of cGvHD as a single entity.
• These findings have the potential to guide the development of more personalized and effective therapeutic strategies for cGvHD.
• Further research is warranted to validate these subtypes and explore their clinical implications in diverse patient populations.